Contact
Please use this form to send email to PR contact of this press release:
BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer
TO:
Please use this form to send email to PR contact of this press release:
BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer
TO: